Abstract:Viral hepatitis C infection is one of the main causes of the hepatitis after blood transfusion and hepatitis C virus (HCV) infection is a global health threat. The HCV NS5B polymerase, an RNA dependent RNA polymerase (RdRp) and an essential role in the replication of the virus, has no functional equivalent in mammalian cells. So the research and development of efficient NS5B polymerase inhibitors provides a great strategy for antiviral therapy against HCV. A combined three-dimensional quantitative structure activity relationship (QSAR) modeling was accomplished to profoundly understand the structure activity correlation of a train of indole-based inhibitors of the HCV NS5B polymerase to against HCV. A comparative molecular similarity indices analysis (COMSIA) model as the foundation of the maximum common substructure alignment was developed. The optimum model exhibited statistically significant results: the cross-validated correlation coefficient q(2) was 0.627 and non-cross-validated r2 value was 0.943. In addition, the results of internal validations of bootstrapping and Y-randomization confirmed the rationality and good predictive ability of the model, as well as external validation (the external predictive correlation coefficient Lixt = 0.629). The information obtained from the COMSIA contour maps enables the interpretation of their structure activity relationship. Furthermore, the molecular docking study of the compounds for 3TYV as the protein target revealed important interactions between active compounds and amino acids, and several new potential inhibitors with higher activity predicted were designed basis on our analyses and supported by the simulation of molecular docking. Meanwhile, the OSIRIS Property Explorer was introduced to help select more satisfactory compounds. The satisfactory results from this study may lay a reliable theoretical base for drug development of hepatitis C virus NS5B polymerase inhibitors. (C) 2016 Elsevier B.V. All rights reserved.

Recent Progress of Non-Structural 5A Protein(ns5a) Inhibitors As Anti-Hepatitis Virus C Agents

The Changing Face of Hepatitis C: Recent Advances on Hcv Inhibitors Targeting Ns5a

New Non-Nucleocide Ns5b Protein Inhibitors For The Treatment Of Chronic Hepatitis C Infection

Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors

Recent Advances on the Synthesis of Hepatitis C Virus NS5B RNA-dependent RNA-polymerase Inhibitors.

Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

Small Molecule NS5B RdRp Non-Nucleoside Inhibitors for the Treatment of HCV Infection: A Medicinal Chemistry Perspective.

Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein

HCV Non-Nucleoside NS5B Polymerase Inhibitors

Recent progress of hepatitis virus C targets and small molecule inhibitors

Recent advancement in small molecules as HCV inhibitors.

Inhibition of hepatitis C virus infection by NS5A-specific aptamer.

Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

Advance in the Research of the Nonstructural Protein NS2 of Hepatitis C Virus

Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)

Characterizations of HCV NS5A replication complex inhibitors.

3D-QSAR and Molecular Docking Studies on Designing Inhibitors of the Hepatitis C Virus NS5B Polymerase

Non-Nucleoside Inhibitors Of Ns5b Polymerase Binding To Allosteric Sites: 3d-Qsar And Molecular Docking Studies

Recent Advance in Antiviral Drugs for Hepatitis C.

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

The Development of Novel HCV NS3-4A Protease Inhibitors